Acumen Pharmaceuticals, Inc.
NASDAQ:ABOSBiotechnology
Healthcare
$2.29 +0.67%
+$0.02 today
- Market cap
- $165.63M
- Beta
- 0.35
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$1.79
52W Low $1.10High $3.60
Volume 0.81M
Average 0.40M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$115.54M
FY 2025 · Annual
Investing Cash Flow
$133.93M
FY 2025 · Annual
+178.9% YoYFinancing Cash Flow
-$34,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.61M) | (42.86M) | (52.37M) | (102.33M) | (121.34M) |
| Depreciation & Amortization | 4K | 169K | 184K | 178K | (751K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 922K | 3.06M | 6.15M | 9.64M | 9.85M |
| Change in Working Capital | 298K | 3.99M | 3.87M | 11.65M | (5.12M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 557K | 552K | (261K) | 4.27M | (5.09M) |
| Other Working Capital | (259K) | 3.43M | 4.13M | 7.38M | (25K) |
| Other Non-Cash Items | 81.42M | 487K | (888K) | (5.35M) | 1.82M |
| Operating Cash Flow | (17.96M) | (35.15M) | (43.06M) | (86.22M) | (115.54M) |
| Capital Expenditures | (40K) | (161K) | (21K) | (16K) | (88K) |
| Acquisitions (Net) | 0 | (39.35K) | 3K | 0 | 0 |
| Purchases of Investments | (104.08M) | (41.51M) | (250.63M) | (170.73M) | (38.06M) |
| Sales of Investments | 0 | 80.86M | 78.98M | 218.77M | 172.08M |
| Other Investing Activities | 0 | 39.35K | 0 | 0 | 0 |
| Investing Cash Flow | (104.12M) | 39.19M | (171.67M) | 48.03M | 133.93M |
| Debt Repayment | 0 | 0 | 30M | (739K) | 0 |
| Common Stock Issued | 168.56M | 3.79M | 121.9M | 7.94M | 39K |
| Common Stock Repurchased | 0 | 0 | 0 | (41K) | (73K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.88M | 115K | (151K) | (230K) | 0 |
| Financing Cash Flow | 200.47M | 3.91M | 151.75M | 6.93M | (34K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 78.39M | 7.94M | (62.98M) | (31.26M) | 18.36M |
| Free Cash Flow | (18M) | (35.31M) | (43.09M) | (86.23M) | (115.63M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$121.3M
+ D&A-$751.0K
+ Stock-Based Comp$9.9M
+ Deferred Tax$0
- Working Capital-$5.1M
+ Other Non-Cash$1.8M
= Operating Cash Flow-$115.5M
- Capex-$88.0K
= Free Cash Flow-$115.6M
Analysis
FY2025 free cash flow is -$115.6M. FCF conversion is 95.3% of net income. Operating cash flow was -$115.5M, with capex of -$88.0K. The largest bridge item is Stock-Based Comp at $9.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Sep 16, 2026 | |
| S-8 | S-8 filing | Aug 12, 2026 | |
| 8-K | Current report | Aug 12, 2026 | |
| 10-Q | Quarterly report | Aug 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Jun 17, 2026 |
Does ABOS generate free cash flow?
Acumen Pharmaceuticals, Inc. (ABOS) generated -$115.63M of free cash flow in fiscal 2025.
How much operating cash flow does ABOS produce?
Operating cash flow was -$115.54M, before capital expenditures of $88,000.00.
Continue the stock analysis
Jump to another research area for this company.